Hyaluronic acid inhalant, and preparation method and application thereof

Abstract

The invention provides a hyaluronic acid inhalant. The hyaluronic acid inhalant comprises oligo hyaluronic acid or a salt thereof and oligomeric hyaluronic acid or a salt of oligomeric hyaluronic acid, the mass content of oligo hyaluronic acid or salt thereof is 0.01%-5%, preferably 0.3%-2%, and the mass content of oligomeric hyaluronic acid is 0.01%-5%, preferably 0.1%-1%. The hyaluronic acid inhalant prepared by the invention can be widely applied to respiratory diseases such as rhinitis, pharyngitis, bronchitis, asthma, cough, chronic obstructive pulmonary disease and the like. The hyaluronic acid inhalant increases viscosity of medicines, prolongs the retention time of effective components of the medicines in nasal mucosa, improves the bioavailability of the medicines, is beneficial tomaintaining the space structure of pulmonary elastic fibers and preventing the deterioration of diseases, can effectively treat obstructive chronic lung diseases and reconstruct lung functions, and can also effectively prevent recurrence of lung diseases. The hyaluronic acid inhalant obtained by combining hyaluronic acid with a low molecular weight and oligomeric hyaluronic acid.

Description

technical field [0001] The present application relates to the technical field of pharmaceuticals, in particular to a hyaluronic acid inhaler and its preparation method and application. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and / alveolar abnormalities, often associated with significant exposure to toxic particles related to gas. The exact etiology of COPD is still unclear, and the risk factors that have been found can be roughly divided into two categories: external factors (environmental factors) and internal factors (individual susceptibility factors). [0003] The 2019 Global Chronic Obstructive Pulmonary Disease Diagnosis, Management and Prevention Strategy Report lists the current main drugs for the treatment of COPD, including β2 agonists, anticholinergic drugs, and inhaled glucocorticoids, etc., but th...

AI Technical Summary

Problems solved by technology

[0003] The 2019 Global Chronic Obstructive Pulmonary Disease Diagnosis, Management and Prevention Strategy Report lists the current main drugs for the treatment of COPD, including β2 agonists, anticholinergic drugs, and inhaled glucocorticoids, etc., but the use of these drugs alone Or combined use has obvious side effects, and the efficacy is limited, so the development of new drugs with high efficacy and no side effects is the main research direction at present.

The average molecular weight of hyaluronic acid is between 50,000 and 5 million Daltons. High-molecular-weight hyaluronic acid has the potential problem of incomplete nebulization during spray treatment, and it also has the potential of not being able to reach the distal end of the lungs and has low bioavailability. low problem

Images